TONIX PHARMACEUTICALS HOLDIN (TNXP) Stock Analyst Earnings Estimates
NASDAQ:TNXP - Nasdaq - US8902608475 - Common Stock
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | ||
|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 7.768M | 12.795M 64.71% | 15.929M 24.49% | 41.708M 161.84% | |||
| EBITDA YoY % growth | -92.26M -82.77% | -110.84M -20.14% | -114.089M -2.93% | N/A | N/A | N/A | |
| EBIT YoY % growth | -92.31M -82.76% | -112.09M -21.43% | -118.38M -5.61% | -80.871M 31.69% | -78.094M 3.43% | -64.577M 17.31% | |
| Operating Margin | N/A | N/A | -1,523.94% | -632.05% | -490.26% | -154.83% | |
| EPS YoY % growth | -1,664.00 63.89% | -814.00 51.08% | -275.84 66.11% | -14.41 94.78% | -23.03 -59.84% | -0.83 96.41% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -3.03 88.99% | -5.55 3.67% | -5.55 71.22% | -5.71 -2,383.48% | -5.55 -83.16% |
| Revenue Q2Q % growth | 3.468M -8.23% | 4.182M 68.49% | 4.743M 114.81% | 4.743M 68.07% | 5.304M 52.94% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -21.308M 22.03% | -20.375M 4.57% | -21.26M -15.80% | -21.871M -40.61% | -25.079M -17.70% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.23 99.61% | -2.99 | 2.76 | 92.31% |
| Q2 2024 Q2Q % growth | -19.28 77.52% | -3.34 | -15.94 | -477.45% |
| Q1 2024 Q2Q % growth | -5.76 94.46% | -12.73 | 6.97 | 54.75% |
| Q4 2023 Q2Q % growth | -27.52 75.43% | -53.64 | 26.12 | 48.69% |
| Q3 2023 Q2Q % growth | -58.56 57.57% | -48.63 | -9.93 | -20.41% |
| Q2 2023 Q2Q % growth | -85.76 64.85% | -89.92 | 4.16 | 4.63% |
| Q1 2023 Q2Q % growth | -104.00 67.50% | -98.94 | -5.06 | -5.11% |
| Q4 2022 Q2Q % growth | -112.00 75.00% | -175.44 | 63.44 | 36.16% |
| Q3 2022 Q2Q % growth | -138.00 56.88% | -208.08 | 70.08 | 33.68% |
| Q2 2022 Q2Q % growth | -244.00 45.54% | -294.78 | 50.78 | 17.23% |
| Q1 2022 Q2Q % growth | -320.00 28.57% | -304.66 | -15.34 | -5.03% |
| Q4 2021 Q2Q % growth | -448.00 30.00% | -391.68 | -56.32 | -14.38% |
| Q3 2021 Q2Q % growth | -320.00 44.44% | -456.96 | 136.96 | 29.97% |
| Q2 2021 Q2Q % growth | -448.00 69.57% | -424.32 | -23.68 | -5.58% |
| Q1 2021 Q2Q % growth | -448.00 76.67% | -359.04 | -88.96 | -24.78% |
| Q4 2020 Q2Q % growth | -640.00 96.50% | -489.60 | -150.40 | -30.72% |
| Q3 2020 Q2Q % growth | -576.00 98.42% | -718.08 | 142.08 | 19.79% |
| Q2 2020 Q2Q % growth | -1,472.00 97.58% | -1,468.80 | -3.20 | -0.22% |
| Q1 2020 Q2Q % growth | -1,920.00 97.67% | -2,056.32 | 136.32 | 6.63% |
| Q4 2019 Q2Q % growth | -18,304.00 | -9,726.72 | -8,577.28 | -88.18% |
| Q3 2019 Q2Q % growth | -36,416.00 | -28,396.80 | -8,019.20 | -28.24% |
| Q2 2019 Q2Q % growth | -60,800.00 | -64,409.82 | 3,609.82 | 5.60% |
| Q1 2019 Q2Q % growth | -82,560.00 | -70,502.40 | -12,057.60 | -17.10% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | 2.822M -29.26% | 3.145M | -323K | -10.27% |
| Q2 2024 Q2Q % growth | 2.208M | 3.57M | -1.362M | -38.15% |
| Q1 2024 Q2Q % growth | 2.482M | 3.876M | -1.394M | -35.96% |
| Q4 2023 Q2Q % growth | 3.779M | 3.91M | -131K | -3.35% |
| Q3 2023 Q2Q % growth | 3.989M | 5.916M | -1.927M | -32.57% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | -89.17% | 0% | 7.08% |
| Revenue | 0% | -60.92% | 0% | 1.35% |